Actively Recruiting
A Self-Controlled Study on the Treatment of Restless Legs Syndrome in Uremia With Dipyridamole
Led by Yunfeng Xia · Updated on 2026-04-22
80
Participants Needed
1
Research Sites
66 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this clinical trial is to determine whether dipyridamole can treat restless legs syndrome in patients with uremia. In addition, the safety of dipyridamole will also be evaluated. The main questions this study aims to answer include: Can dipyridamole improve the symptoms of restless legs syndrome in participants? Can dipyridamole improve participants' anxiety, depression, sleep quality, and quality of life? What adverse reactions might participants experience while taking dipyridamole? This study is a self-controlled trial in which all participants receive active drug treatment. Participants will take dipyridamole daily (50 mg per dose, three times a day) for 12 weeks. The efficacy of dipyridamole will be evaluated by comparing relevant scale scores and laboratory indicators before and after treatment. In addition, adverse reactions during the treatment follow-up will be monitored to assess the safety of dipyridamole in this patient population.
CONDITIONS
Official Title
A Self-Controlled Study on the Treatment of Restless Legs Syndrome in Uremia With Dipyridamole
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Maintenance hemodialysis for at least 3 months
- Age between 18 and 75 years
- Diagnosed with Restless Legs Syndrome with a score greater than 15 on the International Restless Legs Syndrome Rating Scale
- Willing to cooperate with this study
You will not qualify if you...
- Having other cerebrovascular, muscular, or movement system diseases that affect the assessment of restless legs syndrome
- Active bleeding such as gastrointestinal bleeding or intracerebral hemorrhage
- Long-term use of dipyridamole
- Use of medications affecting restless legs syndrome within the last 3 weeks, including dopamine agonists/antagonists, tricyclic antidepressants, lithium, etc.
- History of psychosis
- Pregnant or breastfeeding women
- Allergy or intolerance to dipyridamole
- Unable or unwilling to cooperate with this study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China, 400016
Actively Recruiting
Research Team
Y
yunfeng xia
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here